Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
894 USD | -0.80% | -2.86% | +1.79% |
Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
Apr. 17 | The market is pinning its hopes on earnings reports |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.79% | 96.07B | |
-3.30% | 102B | |
-1.19% | 21.66B | |
-18.35% | 20.77B | |
-8.07% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B | |
-21.69% | 8.57B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, 2022